文献速递眼底病与葡萄膜炎

临床实践中抗血管内皮生长因子治疗糖尿病黄斑水肿后的视力结局

Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice.
PubMed 文献 · Am J Ophthalmol · 2018-04-21

该回顾性干预队列研究分析了Geisinger健康系统2007年1月至2012年5月启动抗血管内皮生长因子(anti-VEGF)治疗的110例糖尿病黄斑水肿患者(121只眼),12个月内平均注射3.1次、就诊9.2次,平均视力改善+4.7个字母,提示临床实践中监测和注射频率低于里程碑临床试验,视力结局较差。

要点

  • 12个月内平均注射3.1次,68.6%的眼接受≤3次注射。
  • 12个月时平均视力改善+4.7个字母,基线平均56.9个字母。
  • 前6个月接受辅助激光的33只眼与未激光的88只眼12个月视力变化相似(+3.1 vs +5.3个字母)。

核心结论

  • 临床实践中接受anti-VEGF治疗的糖尿病黄斑水肿患者监测和玻璃体腔注射频率较低,视力结局劣于里程碑临床试验中的患者。

研究设计与样本

  • 回顾性干预队列研究,分析Geisinger健康系统电子病历数据,纳入2007年1月至2012年5月启动玻璃体腔注射雷珠单抗或贝伐珠单抗治疗的110例患者(121只研究眼),基线矫正视力20/40至20/320,随访期间至少1次眼科医生就诊。

主要发现

  • 12个月内平均眼科医生就诊次数为9.2次,平均玻璃体腔注射次数为3.1次(范围1-12次),大多数眼(68.6%)接受≤3次注射。
  • 12个月时平均矫正视力变化为+4.7个字母(基线平均56.9个字母)。
  • 12个月时视力 gaining≥10个或≥15个字母的眼比例分别为31.4%和24.0%,视力丢失≥10个或≥15个字母的眼比例分别为10.8%和8.3%。
  • 前6个月接受辅助激光的33只眼与未接受激光的88只眼12个月矫正视力变化相似(+3.1 vs +5.3个字母)。

关键数值与推荐

  • 12个月内平均注射3.1次(范围1-12次),68.6%的眼接受≤3次注射。
  • 12个月时平均矫正视力变化+4.7个字母(基线平均56.9个字母)。
  • 12个月时 gaining≥10个字母的眼占31.4%,gaining≥15个字母的眼占24.0%。
  • 12个月时丢失≥10个字母的眼占10.8%,丢失≥15个字母的眼占8.3%。
  • 前6个月辅助激光眼(n=33)与未激光眼(n=88)12个月视力变化分别为+3.1和+5.3个字母。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine monitoring and treatment patterns and vision outcomes in real-world patients initiating anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME). DESIGN: Retrospective interventional cohort study. METHODS: Setting: Electronic medical record analysis of Geisinger Health System data. STUDY POPULATION: A total of 110 patients (121 study eyes) initiating intravitreal ranibizumab or bevacizumab for DME during January 2007‒May 2012, with baseline corrected visual acuity of 20/40 to 20/320, and ≥1 ophthalmologist visit during follow-up. MAIN OUTCOME MEASURES: Intravitreal injections per study eye during the first 12 months; corrected visual acuity, change in corrected visual acuity from baseline, proportions of eyes with ≥10 or ≥15 approximate Early Treatment Diabetic Retinopathy Study letter gain/loss at 12 months; number of ophthalmologist visits. RESULTS: Over 12 months, mean number of ophthalmologist visits was 9.2; mean number of intravitreal injections was 3.1 (range, 1-12), with most eyes (68.6%) receiving ≤3 injections. At 12 months, mean corrected visual acuity change was +4.7 letters (mean 56.9 letters at baseline); proportions of eyes gaining ≥10 or ≥15 letters were 31.4% and 24.0%, respectively; proportions of eyes losing ≥10 or ≥15 letters were 10.8% and 8.3%, respectively. Eyes receiving adjunctive laser during the first 6 months (n = 33) showed similar change in corrected visual acuity to non-laser-treated eyes (n = 88) (+3.1 vs +5.3 letters at 12 months). CONCLUSIONS: DME patients receiving anti-VEGF therapy in clinical practice undergo less frequent monitoring and intravitreal injections, and achieve inferior vision outcomes to patients in landmark clinical trials.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Holekamp NM, Campbell J, Almony A, et al. Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice. Am J Ophthalmol. 2018. PMID: 29684329. doi:10.1016/j.ajo.2018.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。